Abstract
Hybrid imaging using PET/MRI in liver and pancreas uses the enhanced tissue contrast of magnetic resonance including dynamic enhancement using gadolinium based contrast agent with early extracellular and late hepatospecifc distribution with addition of the evaluation of the metabolic activity of the tissues. Te possibility of the synchronous data acquisition with the breathing movements improves the detectability of the presence and level of the metabolic activity within the lesions. 18F-fluorodeoxyglucose is being an optimal radiopharmaceutical in detection and follow-up of the liver metastases and cholangiogenous tumors.
Te hepatocellular carcinoma imaging could be based both on the 18F-fluorodeoxyglucose and 18F-fluorocholine. I tis the advantage to combine magnetic resonance and positron emission tomography in patients with pancreatic tumors, including the assessment of the behavior and in the evaluation of the staging of the tumor, especially in cases when the hepatic metastases of pancreatic tumors should be excluded.
In tumors of neuroendocrine origin even in pancreatic or liver secondary tumors, the useful radiopharmaceutical is 18F-fluorodihydroxyphenylalanine.